Results 141 to 150 of about 519,309 (312)
Pharmaceutical Prices and Political Activity [PDF]
Drug prices have been a conspicuous political issue in much of recent history, but no more so than during health care reform debates in 1993 and 1994.
Catherine Wolfram, Sara Fisher Ellison
core
A comparative study of the patentability standards with respect to pharmaceutical inventions in the United Kingdom and South Africa [PDF]
, 2014 Using a comparative methodology the thesis analyses the patentability of pharmaceutical and related inventions in the UK and South Africa. The viewpoint adopted is that of the industry actors, who are engaged in the conception through to the ...
Dludlu, Celucolo Peter
core
Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree +9 more
wiley +1 more source
Explaining Pharmaceutical R&D Growth Rates at the Industry Level: New Perspectives and Insights [PDF]
This paper uses aggregate data for the major pharmaceutical companies in the U.S. to study the rate of growth in pharmaceutical R&D intensity over the period from 1952 to 2001.
Santerre, Rexford +2 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Digital technologies hold promise for transforming healthcare by enhancing personalized treatments and offer valuable opportunities to improve patient care. Here, we evaluated several novel, self‐administered, home‐based, digital endpoints for their association with corresponding conventional standard clinical measures (primary) in ...
Arne Mueller +14 more
wiley +1 more source
Regulatory ambivalence and the limitations of pharmaceutical policy in Spain [PDF]
Broadly speaking, pharmaceutical policy in Spain has been unable to control either the price or the volume of drugs prescribed. Limited attempts have been made to bring together the regulation of the pharmaceutical market and policies, in pursuit of the ...
Jaume Puig, Joan Costa
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers +19 more
wiley +1 more source
A study on influencers of total sales revenue of generic pharmaceutical companies in Indonesia [PDF]
This paper empirically examines the influence of firms’ one-year lagged of total new products (t-1), one-year lagged profitability (t-1), and market share of new products to firms’ amount of sales revenue in pharmaceutical generic companies in Indonesia.
Tjandrawinata, Raymond R. +1 more
core +1 more source
Electrostatic charge in pharmaceutical systems [PDF]
, 2013 Electrostatic technology has been applied in novel applications such as electrospraying for respiratory delivery and pharmaceutical sterilization. Results from computational models suggest that charges on aerosolized particles may affect deposition in ...
Kwok, PCL, Chan, HK
core